These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25792640)

  • 21. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological treatment of COPD and future of anti-inflammatory therapy].
    Watz H; Bitter-Suermann S; Kanniess F; Magnussen H
    Med Klin (Munich); 2006 Apr; 101(4):283-92. PubMed ID: 16607484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are your COPD patients benefiting from best practices?
    Gianakos D; Kaczynski R
    J Fam Pract; 2008 Aug; 57(8):532-6. PubMed ID: 18687229
    [No Abstract]   [Full Text] [Related]  

  • 24. COPD in 2016: some answers, more questions.
    Labaki WW; Martinez CH; Han MK
    Lancet Respir Med; 2016 Dec; 4(12):941-943. PubMed ID: 27890500
    [No Abstract]   [Full Text] [Related]  

  • 25. Triple therapy for the management of COPD: a review.
    Gaebel K; McIvor RA; Xie F; Blackhouse G; Robertson D; Assasi N; Hernandez P; Goeree R
    COPD; 2011 Jun; 8(3):206-43. PubMed ID: 21513437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Asthma and COPD: guidance in the jungle of inhalative drugs].
    Hering T
    MMW Fortschr Med; 2015 May; 157(10):59, 61-2. PubMed ID: 26019099
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of pharmacotherapy in mild to moderate chronic obstructive pulmonary disease.
    Raghavan N; Guenette JA; O'Donnell DE
    Ther Adv Respir Dis; 2011 Aug; 5(4):245-54. PubMed ID: 21357348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease.
    Currie GP; Rossiter C; Miles SA; Lee DK; Dempsey OJ
    Pulm Pharmacol Ther; 2006; 19(2):112-9. PubMed ID: 15970450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choice of medications when treating stable COPD.
    Vestbo J
    Clin Respir J; 2010 Oct; 4(4):195-6. PubMed ID: 20887340
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug therapy of airway obstruction. "Completely different for asthma and COPD"].
    MMW Fortschr Med; 2008 May; 150(20):14, 16. PubMed ID: 18605635
    [No Abstract]   [Full Text] [Related]  

  • 32. [Phosphodiesterase-4 inhibitors: roflumilast].
    Izquierdo Alonso JL
    Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of COPD: a review].
    Steurer-Stey C
    Praxis (Bern 1994); 2004 Oct; 93(41):1673-8. PubMed ID: 15535600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results.
    Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I
    BMJ Open; 2018 Mar; 8(3):e019475. PubMed ID: 29581202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
    D'Souza AO; Smith MJ; Miller LA; Kavookjian J
    Chest; 2006 Jun; 129(6):1693-708. PubMed ID: 16778291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 37. Treating COPD--the TORCH trial, P values, and the Dodo.
    Rabe KF
    N Engl J Med; 2007 Feb; 356(8):851-4. PubMed ID: 17314345
    [No Abstract]   [Full Text] [Related]  

  • 38. Preventing acute exacerbations and hospital admissions in COPD.
    Marchetti N; Criner GJ; Albert RK
    Chest; 2013 May; 143(5):1444-1454. PubMed ID: 23648908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
    Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
    Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness
    Woodcock A; Boucot I; Leather DA; Crawford J; Collier S; Bakerly ND; Hilton E; Vestbo J
    Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29467200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.